R. Walker

发表

Anti-HIV State but Not Apoptosis Depends on IFN Signature in CD4+ T Cells

R. Dummer, H. Joller, H. Simon, 2006, The Journal of Immunology.

Quantitation of peripheral blood markers of rat experimental autoimmune encephalomyelitis

B. Jaffee, T. Ocain, E. Izmailova, 2007, Autoimmunity.

PKC-θ-Deficient Mice Are Protected from Th1-Dependent Antigen-Induced Arthritis

M. Silva, B. Jaffee, S. Chandra, 2006, The Journal of Immunology.

First-in-human, multicenter, dose-escalation, phase I study of the investigational drug TAK-733, an oral MEK inhibitor, in patients (pts) with advanced nonhematologic malignancies and melanoma.

J. Sosman, A. Ribas, P. LoRusso, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Persistent expression of chemokine and chemokine receptor RNAs at primary and latent sites of herpes simplex virus 1 infection

D. Coen, W. Cook, D. Knipe, 2004, Virology Journal.

Stimulated trans-acting factor of 50 kDa (Staf50) inhibits HIV-1 replication in human monocyte-derived macrophages.

R. Andreesen, A. Bouazzaoui, H. von Briesen, 2006, Virology.

Combining IMGN779, a Novel Anti-CD33 Antibody-Drug Conjugate (ADC), with the PARP Inhibitor, Olaparib, Results in Enhanced Anti-Tumor Activity in Preclinical Acute Myeloid Leukemia (AML) Models

E. Wang, Scott M. Portwood, R. Walker, 2016 .

IMGN779, a CD33-Targeted Antibody-Drug Conjugate (ADC) with a Novel DNA-Alkylating Effector Molecule, Induces DNA Damage, Cell Cycle Arrest, and Apoptosis in AML Cells.

A. Romanelli, W. Krystal, N. Fishkin, 2015 .

The Antibody-Drug Conjugate (ADC) IMGN779 Is Highly Active in Vitro and in Vivo Against Acute Myeloid Leukemia (AML) with FLT3-ITD Mutations

R. Lutz, G. Schuurhuis, G. Ossenkoppele, 2014 .

CXCR4 tropic human immunodeficiency virus type 1 induces an apoptotic cascade in immature infected thymocytes that resembles thymocyte negative selection.

V. Planelles, D. Powell, D. Camerini, 2006, Virology.

Phase I, dose-escalation study of the investigational drug TAK-733, an oral MEK inhibitor, in patients (pts) with advanced solid tumors.

R. Neuwirth, J. Sosman, A. Ribas, 2013 .

PKC-theta-deficient mice are protected from Th1-dependent antigen-induced arthritis.

B. Jaffee, S. Chandra, D. Picarella, 2006, Journal of immunology.

Characterization of primitive marrow CD34+ cells that persist after a sublethal dose of total body irradiation.

N. Mahmud, Veena S Patil, R. Hoffman, 2005, Experimental hematology.

MLN2480, an investigational oral pan-RAF kinase inhibitor, in patients (pts) with relapsed or refractory solid tumors: Phase I study.

R. Neuwirth, M. Kneissl, D. Rasco, 2013 .